The National Cancer Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to Sangam Lifesciences, Inc., based in Denver, Colorado. This license would allow Sangam to develop and sell a new drug delivery system using a synthetic polymer called poly (L-lysine succinylated) for treating cancer in both humans and animals. The drug delivery platform targets specific cells and tissues using negatively charged polymers to release drugs in a controlled manner. The license will be exclusive for cancer treatments, while other uses of the platform are still available for licensing.
Simple Explanation
The National Cancer Institute is thinking about letting a company called Sangam Lifesciences be the only one to use a special delivery system to give medicine for cancer in people and animals. This is like giving them a special key to unlock a way to treat cancer that nobody else can use for a while.